Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Crescent Biopharma, Inc.NASDAQ: CBIO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization remains negative

Q1 FY2026 depreciation & amortization was $64K, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $148K. Over 3 fiscal years it compounded at -26.0% a year.

Context

  • Depreciation & amortization amounted to 0.8% of revenue in FY2025.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly depreciation & amortization holds near $64K or moves back toward the trailing-twelve-month quarterly average of $37K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$64K+18.5% QoQ
Last fiscal yearDec 2025
$84K+138.8% YoY
LTMMar 2026
$148K-99.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+138.8%——
3-year CAGR-26.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
84K USD
Year-over-year change
+138.8%
4-year CAGR
-24.9%

Depreciation & Amortization vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -99.6% is the lowest of 9, against a peer median of -15.7%.
  • Depreciation & amortization amounts to 1.2% of revenue for CBIO, versus a peer median of 4.0%.
CBIO Competitors
Depreciation & Amortization for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M USD+0.0%+18.6%8.5%
ZYMEZymeworks Inc.LTM Sep 2026$8.21M USD-35.8%-2.5%3.1%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.24M USD-26.3%-17.4%3.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$1.12M USD-32.0%-8.2%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥1.03M CNY-95.7%-55.8%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$148K USD-99.6%-26.0%1.2%
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
CGENCompugen Ltd.LTM Mar 2026$0 USD—-0.5%0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —-15.7%-2.5%4.0%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.